Based on the AstraZeneca PLC ADR stock forecast from 5 analysts, the average analyst target price for AstraZeneca PLC ADR is USD 87.38 over the next 12 months. AstraZeneca PLC ADR’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of AstraZeneca PLC ADR is Slightly Bullish , which is based on 9 positive signals and 7 negative signals. At the last closing, AstraZeneca PLC ADR’s stock price was USD 74.22. AstraZeneca PLC ADR’s stock price has changed by +0.87% over the past week, +9.21% over the past month and +15.73% over the last year.
No recent analyst target price found for AstraZeneca PLC ADR
No recent average analyst rating found for AstraZeneca PLC ADR
Company Overview AstraZeneca PLC ADR
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Read Less
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga...Read More
Frequently Asked Questions About AstraZeneca PLC ADR (AZN) Stock
Based on ratings from 5 analysts AstraZeneca PLC ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 7 buy, sell and 1 hold ratings.
AZN stock's dividend yield is 2.08%.
Our analysis grades AZN stock's dividend yield at F. This means that AZN stock's dividend yield is above 38% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this AZN may be a poor dividend stock for its sector.
Based on targets from 5 analysts, the average taret price for AZN is USD 87.38 over the next 12 months. The maximum analyst target price is USD 94.33 while the minimum anlayst target price is USD 78.
AZN stock's Price/Earning ratio is 33.14.
Our analysis grades AZN stock's Price / Earning ratio at F. This means that AZN stock's Price/Earning ratio is above 50% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this AZN may be fairly valued for its sector
The last closing price of AZN's stock was USD 74.22.
The most recent market capitalization for AZN is USD 228.18B.
Based on targets from 5 analysts, the average taret price for AZN is projected at USD 87.38 over the next 12 months.
This means that AZN's stock price may go up by +17.73% over the next 12 months.
We can't find any ETFs which contains AstraZeneca PLC ADR's stock.
As per our most recent records AstraZeneca PLC ADR has 0 Employees.
AstraZeneca PLC ADR's registered address is 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA.
You can get more information about it from AstraZeneca PLC ADR's website at https://www.astrazeneca.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced on free cash flow basis
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Frequently Asked Questions About AstraZeneca PLC ADR (AZN) Stock
Based on ratings from 5 analysts AstraZeneca PLC ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 7 buy, sell and 1 hold ratings.
AZN stock's dividend yield is 2.08%.
Our analysis grades AZN stock's dividend yield at F. This means that AZN stock's dividend yield is above 38% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this AZN may be a poor dividend stock for its sector.
Based on targets from 5 analysts, the average taret price for AZN is USD 87.38 over the next 12 months. The maximum analyst target price is USD 94.33 while the minimum anlayst target price is USD 78.
AZN stock's Price/Earning ratio is 33.14.
Our analysis grades AZN stock's Price / Earning ratio at F. This means that AZN stock's Price/Earning ratio is above 50% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this AZN may be fairly valued for its sector
The last closing price of AZN's stock was USD 74.22.
The most recent market capitalization for AZN is USD 228.18B.
Based on targets from 5 analysts, the average taret price for AZN is projected at USD 87.38 over the next 12 months.
This means that AZN's stock price may go up by +17.73% over the next 12 months.
We can't find any ETFs which contains AstraZeneca PLC ADR's stock.
As per our most recent records AstraZeneca PLC ADR has 0 Employees.
AstraZeneca PLC ADR's registered address is 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA.
You can get more information about it from AstraZeneca PLC ADR's website at https://www.astrazeneca.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AZN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
